Takayuki Arai

Chiba University

Papers

2

Total Citations

5

H-Index

2

About

Dr. Takayuki Arai is a leading urologic oncologist whose research focuses on advancing surgical and systemic treatments for renal cell carcinoma (RCC). His major contributions lie in optimizing therapeutic strategies for complex kidney tumors, particularly through the integration of cutting-edge immunotherapy and targeted drug combinations. Dr. Arai’s work on deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab therapy—a case study that has garnered 3 citations—demonstrates the growing potential of immuno-oncology agents with tyrosine kinase inhibitors in managing metastatic RCC. Additionally, his pioneering research on off-clamp robot-assisted partial nephrectomy for renal hilar tumors (2 citations) showcases his commitment to refining minimally invasive surgical techniques that preserve renal function while improving patient outcomes. By bridging the gap between novel pharmacotherapies and advanced surgical approaches, Dr. Arai’s contributions are shaping modern urologic oncology, offering new hope for patients with challenging renal malignancies. His work continues to influence clinical practice and inspire further investigation into personalized, multimodal cancer care.

Research Focus

Key Achievements

2
H-Index
2
Papers
5
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
3 citations · 2023
📈 Most Prolific Year: 2023 (2 Papers)
🤝 Key Collaborators: 10
🏛 Institutions: Chiba University

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago